Market closedNon-fractional

Astria Therapeutics/ATXS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Astria Therapeutics

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Ticker

ATXS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

59

ATXS Metrics

BasicAdvanced
$494M
Market cap
-
P/E ratio
-$2.25
EPS
0.81
Beta
-
Dividend rate
$494M
0.81
33.826
33.409
0.046
-16.43%
-28.19%
1.81
1.81
-4.386
-13.26%
-66.49%

What the Analysts think about ATXS

Analyst Ratings

Majority rating from 7 analysts.
Buy

ATXS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$20M
-36.62%
Profit margin
0.00%
NaN%

ATXS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.40%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.63
-$0.94
-$0.38
-
Expected
-$0.49
-$0.49
-$0.78
-$0.36
-$0.39
Surprise
-7.63%
29.63%
20.49%
4.40%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Astria Therapeutics stock?

Astria Therapeutics (ATXS) has a market cap of $494M as of July 05, 2024.

What is the P/E ratio for Astria Therapeutics stock?

The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of July 05, 2024.

Does Astria Therapeutics stock pay dividends?

No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Astria Therapeutics dividend payment date?

Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.

What is the beta indicator for Astria Therapeutics?

Astria Therapeutics (ATXS) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Astria Therapeutics stock

Buy or sell Astria Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing